Use of Dry Powder Mannitol for the Treatment of Chronic Rhinosinusitis
Patients with chronic rhinosinusitis receiving intranasal mannitol powder, compared to standard medical therapies, to alleviate sinusitis symptoms.
Dr Emad Massoud
40 participants
Nov 1, 2012
Interventional
Conditions
Summary
Chronic Rhinosinusitis is a chronic condition of the nose and paranasal sinuses. Patients suffering from chronic sinusitis complain of headaches, nasal congestion and thick nasal discharge. The burden of chronic sinusitis on our society is high. It causes increased cost to health care system and decreased productivity with loss of work days. No single treatment was found to control the symptoms of chronic sinusitis. It was found that dry mannitol delivered to the lungs of patients with cystic fibrosis makes the secretions less thick, easier to clear and symptoms better controlled. We believe these effects are transferrable to chronic sinusitis patients. We believe that mannitol will help loosen their nasal discharge, making it easier to clear and eventually control their symptoms better
Eligibility
Inclusion Criteria1
- Patients with chronic rhinosinusitis (as defined by the Canadian clinical practice guidelines for acute and chronic sinusitis)
Exclusion Criteria2
- Previous sinus surgery
- Allergy or sensitivity to any of the items in the standard medical treatment
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dry mannitol powder (a natural product), delivered intranasally, along with standard medical care (listed below). Mannitol dosing:s 150 mg/puff, patients will be guided to use it as 3 nasal puffs in each nostril three times per day for 6 months
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612001008819